Oxford headquartered T-Cypher Bio announces appointment of Thomas Lars Andresen as Chief Executive Officer

Pictured: Thomas Lars Andresen
Thomas-L.-Andresen-682x1024_2-400×601

T-Cypher Bio, a rapidly emerging private biotech company pioneering a novel approach to TCR therapeutics today announces the appointment of Thomas Lars Andresen as Chief Executive Officer (CEO) and member of the Board of Directors.

T-Cypher Bio is to be led by award winning, cell therapy expert, Thomas Lars Andresen, as it aims to unlock an expansive therapeutic target space by decoding natural T-cell responses in both oncology and autoimmune diseases.

Thomas has over 20 years of experience in biomaterial and biological engineering for drug delivery, immune modulation and cell therapy. Over his career, Thomas has founded several clinical stage immunotherapy companies including Boston-based Torque Therapeutics and Monta Biosciences in 2015, and cancer imaging company Nanovi in 2013. He has received multiple research prizes including the Elite Research Prize from the Danish Ministry of Science for his research and contribution to the field, has published more than 200 research articles and filed approximately 45 patent applications.

Uciane Scarlett, PhD, Interim Executive Chair & OSI Investment Principal, said: “Thomas brings a deep expertise of cell therapy drug development and research as we continue to build a leading management team. His appointment as CEO demonstrates our ambition to establish TCypher at the forefront of innovation in the field for deconvoluting vast T cell repertoires. His proven track record will be instrumental to the team as we continue to develop the pipeline and build the Company going forward.”

Thomas Lars Andresen, PhD, CEO said: “T-Cypher’s ground-breaking technologies stand out in the cell therapy space, giving it enormous potential to become a leading force of innovation. TCypher is rapidly growing and it is exciting to join at this stage of the Company’s journey. I look forward to working with the highly ambitious T-Cypher team and driving a unique product pipeline based on the company’s innovative platforms.”

Dr Luke Williams, Head of Immunology, and OSI Scientist-in-Residence said: “Thomas’ experience in the cell therapy field will provide a strong platform for T-Cypher as we continue to rapidly grow and establish our operations. I am looking forward to working alongside him as we enter this new and exciting chapter.”